Basilea Pharmaceutica

Basilea Pharmaceutica Corporate headquarters[5]

Basilea Pharmaceutica was founded in 2000 as a spin-off entity of pharmaceutical giant Hoffman-LaRoche.[6] In 2002, the company founded Basilea Pharmaceutica China Ltd., a research facility located in Haimen Technology Development Zone, north of Shanghai, China, which it operates as a wholly owned subsidiary. Basilea is marketing Toctino (alitretinoin), for the treatment of severe chronic hand eczema, in Denmark, France, Germany, Switzerland and the United Kingdom.[7] The drug is approved in 14 additional European countries as well as in Canada and has been recommended for approval in eight further European countries. Ceftobiprole is acephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus being developed in cooperation with Johnson & Johnson was approved in Europe in October 2013.[8][9] Isavuconazole, a broad-spectrum triazole antifungal drug in Phase III clinical development [10] has won orphan drug status in the United States.[8] Basilea partnered with pharmaceutical company Astellas Pharma Inc., which holds the U.S. rights to the drug, to conduct two phase 3 clinical trials.[11] The trials demonstrated safety and efficacy in adults with invasive fungal infections. Following these trials, the FDA granted approval for the use of isavuconazole in patients with invasive aspergillosis and invasive mucomycoses, diseases that typically occur in immunocompromised patients.[12]

Its products include:

• Isavuconazole, trade name CRESEMBA, an intravenous and oral antifungal[16]
• Ceftobiprole, trade names Zevtera®/Mabelio®, an intravenous broad-spectrum antibiotic suitable for use against methicillin-resistant Staphylococcus aureus (MRSA)[17]
• Alitretinoin, trade name Toctino®, a retinoid-based oral drug
• BAL101553, an oral oncology drug in development for treatment of numerous types of cancer. BAL101553 functions as a tumor checkpoint controller. It is currently in clinical phase 1/2a trials in patients with advanced solid tumors, including bowel, stomach, ovarian, pancreatic and non small cell lung cancers.
• BAL3833, an oral oncology drug candidate, this panRAF inhibitor halts tumour cell proliferation via kinase inhibition. Currently undergoing phase 1 safety trials in patients with advanced solid tumours. One such trial is an 18-month study involving patients with metastatic melanoma sponsored by The Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust.
• BAL30072, an experimental antibiotic. The drug is being adapted for inhalation on the presumption that this delivery method may improve safety and effectiveness in managing these conditions. A 5-year independent study will be carried out on inhalation therapy with BAL30072 by a group of pulmonologists and lung specialists from the inhaled Antibiotics in Bronchiectasis and Cystic fibrosis Consortium (iABC).

• List of pharmaceutical companies
• Pharmaceutical industry in Switzerland